The identification of JAK-STAT pathway mutations in the majority of patients with myeloproliferative neoplasms (MPN) led to the clinical development of JAK inhibitors and resulted in the approval of ruxolitinib for MPN therapy. Despite this important therapeutic advancement, there are significant limitations to JAK inhibitor therapy, both with respect to limited efficacy and dose-limiting toxicities. We hypothesized that alternate dosing regimens allowing for intermittent maximal target inhibition might increase efficacy without inducing added toxicity. Here, by combining experimental and mathematical techniques, we investigated the potential efficacy of varying dosing regimens. We first assessed the effect of ruxolitinib on the growth rate of JAK2V617-positive SET-2 cells exposed to a range of ruxolitinib concentrations. The in vitro data were integrated into a mathematical model to predict responses to varying ruxolitinib concentrations, which were then used to inform candidate dosing schedules to be validated in vivo on a JAKV617F knock-in mouse model. We found that a high-dose intermittent schedule was more efficacious than continuous dosing in vivo, without additional toxicity, suggesting that alternate, intermittent JAK inhibitor dosing strategies should be explored in MPN patients.
The BCR-ABL-negative myeloproliferative neoplasms (MPNs) polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)(1) are clonal disorders of hematopoietic stem or progenitor cells leading to overproduction of myeloid cells (2) . Common to all three are systemic symptoms, increased risk of thrombosis, abnormal bleeding, and progression to acute myeloid leukemia (AML). The only curative treatment is allogeneic stem cell transplantation, which is reserved for patients with high-risk disease without significant comorbidities (3) . The hallmark of BCR-ABL-negative MPNs is constitutive activation of JAK-STAT signaling, including the somatic activating mutation V617F in JAK2 in the majority of MPN patients (4, 5) , JAK2 exon 12 mutations in JAK2V617F-negative PV (6) , and MPL and CALR mutations in JAK2V617F-negative ET/PMF (7, 8) . In each case, these mutations lead to constitutive JAK-STAT signaling (9, 10) suggesting JAK2 as a potential therapeutic target. The first JAK2 inhibitor to enter clinical trials was ruxolitinib (INCB018424), which is FDA-approved for treatment of MF (11) and refractory PV(12). JAK2 inhibitors reduce spleen size, ameliorate systemic symptoms, and improve quality of life; however, they do not achieve significant disease modification in most MPN patients (13) .
The essential role of JAK kinases in hematopoiesis precludes safe, long-term, complete inhibition of JAK2. We therefore explored whether alternative intermittent dosing strategies might offer increased efficacy and/or reduced toxicity in MPN. Previous studies with dasatinib in CML demonstrated an improved therapeutic window with once daily dosing that provides intermittent, potent BCR-ABL inhibition (14) . We therefore sought to identify the optimal dosing schedule for ruxolitinib for MPN treatment by combining mathematical modeling, in vitro and in vivo efficacy and toxicity studies.
To guide our toxicity studies, growth rates of JAK2-mutant SET-2 cells under a range of ruxolitinib concentrations were estimated from flow cytometry apoptosis/viability assays using FITC-Annexin V and 7AAD staining, respectively (BD Pharmingen) (Figures 1 and S1). The estimated rates were used to parameterize a mathematical model of exponential expansion/decline of the cell population under different treatment schedules (Figure 2A and Supplemental materials and methods). The model was constrained by a toxicity curve, which indicates how many consecutive days a given dose is tolerated without inducing murine death (Figures 2B and S3 and Toxicity constraint section in Supplement). Each treatment cycle consisted of a dose given for a certain number of days (the treatment pulse length, T on ) followed by a break, T off . As the toxicity constraint determines how many consecutive days are safe to administer a certain dose (T on ), and the cycle length (T on +T off ) is fixed as one week, a chosen dose uniquely determines the treatment schedule as well as the birth and death rates of the cells. However, drug concentration is not constant over time in vivo but rather it decays exponentially. We fit an exponential decay surface to in vivo pharmacokinetic data in order to approximate the drug concentration at any given time ( Figure 2C , Pharmacokinetic analysis section in Supplement). Efficacy and toxicity of the different treatments in vivo were evaluated based on cohort survival, complete blood counts, liver and spleen weights, and histologic evaluation of bone marrow, spleen, liver and gut (Figures 3, S5 and S6). A non-parametric Wilcoxon rank-sum test was used to determine statistical significance of pairwise comparisons of treatment groups (Table S1 ). All computer simulations were performed using MATLAB 8.5.0 (2015a, The MathWorks Inc., Natick, MA, USA). To enable re-use of our materials and improve reproducibility and transparency we include the MATLAB code and data used for all the analysis and visualizations contained in this paper in the open repository https://github.com/answermyriddles/rux. We created this mathematical modelling framework to investigate disease progression during intermittent and chronic treatment schedules of the JAK inhibitor, ruxolitinib. Our model was parameterized by the growth rates of JAK2V617-positive SET-2 cells exposed to varying doses of ruxolitinib to estimate cell population growth after a treatment cycle of one week ( Figure 2D and Methods). Our modeling approach resulted in two intermittent treatment schedules for which the final simulated cell population growth at the end of the one week treatment cycle was similar to that of a chronic one ( Figure 2D ). The two intermittent treatment schedules selected were 270mg/kg BID and 360mg/kg BID given for five and three consecutive days a week, respectively. Despite the one week predictions for the 360 mg/kg dosing resulting in a larger cell population compared to the chronic treatment (60mg/kg), we decided to test it in vivo as well given the final simulated cell populations were of comparable size ( Figure 2D&S4 ). By nature of being parameterized using in vitro data, our mathematical model is only an approximation and was intended for the purpose of hypothesis generation, pending further investigation in vivo. Instructed by our model we selected a chronic dosing schedule as well as the two aforementioned intermittent schedules to test in an MPN murine model.
The in vivo trial demonstrated that in comparison to a chronic dose of 60 mg/kg BID, 270 mg/kg BID administered five days a week led to equivalent survival (p=0.31 according to a Log-rank test, Figure 3A ) and was more effective at inhibiting JAK2 signaling ( Figure 3B ). Specifically, we observed greater pSTAT5 inhibition in the intermittent 270 mg/kg group compared to the 60 mg/kg chronic group ( Figure 3B ). The intermittent schedule also reduced hemoglobin counts by 25% (p<0.016) ( Figure 3C ) and hematocrit counts by 30% (p<0.016) ( Figure 3D ), without inducing additional hematopoietic or gastrointestinal toxicity ( Figure S6 ). Spleen weights were equivalently reduced for both the 60 mg/kg and 270 mg/kg groups compared to vehicle ( Figure 3E and Supplemental Table 1 ). The intermittent 360 mg/kg schedule, however, induced gastrointestinal toxicity (apparent on gross examination with intestinal edema and erythema) and led to reduced survival compared to other dosing schedules ( Figure 3A) . These results suggest that the intermittent 270 mg/kg ruxolitinib dosing schedule is capable of increasing drug efficacy in the Jak2V617F model without inducing increased toxicity.
Through this study, we sought to test the effects of different ruxolitinib treatment schedules on survival, toxicity and allele burden in a JAKV617F knock-in mouse model. We designed a novel mathematical framework consisting of multiple components (exponential population growth constrained by toxicity and a time/dose dependent pharmacokinetic surface) that, when parameterized using in vitro data, predicted the efficacies of different dosing strategies in silico and allowed us to test hypotheses about the best intermittent treatment strategies to be validated in an in vivo MPN murine model. Based on our in silico model, we predicted that an intermittent treatment strategy could lead to increased efficacy and/or reduced toxicity. We confirmed that increased efficacy could be reached with a 270 mg/kg twice-daily dose for five days followed by a two-day holiday without inducing hematopoietic or gut toxicity. Unfortunately, no treatment group showed differences in the reduction of allele burden, which has only been shown to date in a study by Vannucchi et al, which demonstrated progressive reduction in allele burden in JAK2 pV617F polycythemia vera patients treated with ruxolitinib for up to four years (15) . Of note, our study was only 25 days in duration, and it may take much longer-term studies to see impact on allele burden, which is outside the scope of the current work.
It remains to be understood whether an intermittent treatment could have further beneficial effects such as preventing persistence to the JAK inhibitor after long-term use or whether treatment with JAK inhibitors alone will be enough to completely cure MPNs because of the intrinsic limitation of the mechanism of action of the drug. We demonstrated that by combining in vitro data with mathematical modeling one can efficiently compare intermittent versus chronic dosing regimens and determined that an intermittent schedule is superior in the treatment of an MPN murine model. This study represents an innovative example of how mathematical modeling and biological data can be used to develop novel dosing regimens, an increasingly important question in the cancer and targeted therapy field.
Figure 1. In vitro experimental design using V617F mutated cell line.
In vitro time series FACS measurement of Ruxolitinib-treated SET-2 cells were used to estimate the growth rates of cells over a range of Ruxolitinib concentrations (0, 0.1, 0.5, 1, and 2µM). Birth and death rates were estimated from the time series FACS measurements of the cells stained with apoptosis and viability stains Annexin V and 7AAD, respectively. Each experimental replicate is represented by a different color. The x-axis shows the drug concentrations to which cells were exposed and the y-axes show the rates resulting from estimating the change in live and dead cells obtained from the FACS measurements over a time range of 48 hours for each concentrations of drug exposure. Mean line corresponds to the model fit to all the data and shaded region shows the 95% confidence interval obtained from fitting 100 bootstrapping samples.
Figure 2. Mathematical modeling predicts optimal treatment schedule.
(A) Mathematical model schema. Cell growth is simulated over a 1-week cycle based on in vitro growth rates for a period of continuous daily treatment (Ton) followed by a treatment break (Toff). In the case of chronic dosing, a non-stop treatment is simulated for the whole duration of the 1-week cycle. Treatment schedule (number of Ton days) is uniquely defined, given a chosen dose, by the toxicity constraint. (B) The toxicity constraint was built based on previous knowledge about how many consecutive days different doses could be tolerated in mice. (C) Pharmacokinetic surface. Drug concentration is not constant over time in vivo. An exponentially decaying surface describing the change in plasma concentration as a function of dose (mg/kg) and time is fit to in vivo pharmacokinetic data in order to approximate the drug concentration at any given time. (D) In vivo simulation based on in vitro data. Cell population growth is estimated for different treatment schedules and predicts the optimal treatment schedule of 270mpg for 5 consecutive days to minimize cancer cell population.
Figure 3. In vivo data confirm in silico predictions.
(A) Kaplan-Meier Survival Plot. Group 1 (red) was treated with vehicle twice daily. Group 2 (green) was treated with 60mg/kg twice daily. Group 3 (blue) was treated with 270 mg/kg twice daily for five days followed by a two-day holiday. Group 4 (purple) was treated with 360 mg/kg twice daily for three days followed by a four-day holiday. The 360 mg/kg treatment group showed a significant decrease in survival (p = 0.003) compared to other experimental arms. (B) Western blot. While mice treated with 60 mg/kg ruxolitinib showed partial pSTAT3 and pSTAT5 signaling, mice treated with 270 mg/kg showed nearly complete inhibition of pSTAT5 signaling, indicating there is improved signaling inhibition with increased dose. Complete blood counts measured before and after treatment revealed significant improvement in (C) hemoglobin and (D) hematocrit in group treated with 270 mg/kg BID (5x a week) in comparison to mice treated chronically with 60 mg/kg BID as well as vehicle starting at two weeks after treatment. A non-parametric Wilcoxon rank sum test revealed differences between the 270mg/kg group and two others to be significant with p-values <0.016 for both hemoglobin and hematocrit. Complete results from statistical testing can be found on Supplementary Table 1 . (E) Mice treated with 270 mg/kg BID 5x week and chronic 60 mg/kg BID ruxolitinib showed marked reduction in spleen weight compared to vehicle treatment at the conclusion of 25 days of treatment (p-values of 0.007 comparing treatment groups to vehicle using a Wilcoxon rank sum test). (F) There was no significant change in liver weights between all groups supporting the absence of drug-related toxicity. All pairwise statistical test results for all three groups for liver and spleen can be found in Supplementary Table 1 .
SUPPLEMENTAL MATERIALS AND METHODS

Ruxolitinib (INCB018424)
Ruxolitinib (INCB018424) is a potent and selective JAK1/2 inhibitor that was approved in 2011 for the treatment of myelofibrosis and polycythemia vera (1) . The approval was based on the drug's ability to significantly reduce splenomegaly and ameliorate symptoms through the suppression of JAK2V617-mediated signaling (2) . The ruxolitinib used in this study was synthesized by Incyte and stored at room temperature. A stock solution of the drug was prepared every seven days in citrate buffer with 20% captisol. The vehicle was composed of citrate buffer with 20% captisol. For in vitro experiments, ruxolitinib was prepared in DMSO in 1 mM concentrations and stored at -20 degrees Celsius, and underwent no more than three freeze-thaw cycles.
Murine model, in vivo dosing schedule and analysis of mice
A conditional Jak2V617F knock-in model of polycythemia vera(3) in a CD45.2 background was used for this murine study. Bone marrow from this model was extracted and transplanted into lethally irradiated CD45.1 background recipient mice (see Bone Marrow Transplantation section). Fourteen days post-transplantation, blood counts were collected and mice were randomized into four groups: vehicle, 60 mg/kg ruxolitinib BID, 270 mg/kg ruxolitinib BID five days on and two days off, and 360 mg/kg ruxolitinib BID three days on and four days off. There were five mice in each group.
The average weight for all mice was 0.02 kg and no significant weight loss was observed throughout the study. For the vehicle group, 200 uL vehicle was administered BID for the duration of the study. For the 60 mg/kg group, a stock solution of 60 mg/mL ruxolitinib was prepared and 200 uL were administered to the mice BID. For the 270 mg/mL group, a stock solution of 180 mg/mL ruxolitinib was prepared and 300 uL were administered to the mice BID for five days, followed by a two-day holiday. For the 360 mg/kg group, two doses of 200 uL of 180 mg/mL were administered approximately ten minutes apart BID for three days, followed by a four day holiday ( Figure S4 ). The daily BID treatments were administered approximately 8 hours apart.
All mice were treated with oral gavage for 25 days or until one of the criteria for sacrificing them was met following the guidelines of Memorial Sloan-Kettering Cancer Center Institutional Animal Care and Use Committee-approved animal protocol. Differential blood counts were assessed by submandibular bleeds at two weeks and at the conclusion of the study. Peripheral blood, liver, spleen, bone marrow, and gut were collected at the conclusion of the study. For histopathology, tissues were fixed in 4% paraformaldehyde and then formalin-fixed paraffin-embedded tissue sections were stained using hematoxylin and eosin. Tissue sections were evaluated by a hematopathologist. Bone marrow, spleen and liver cells were collected for flow cytometry.
Bone marrow transplantation
Dissected femurs and tibias from the conditional Jak2V617F knock-in model of polycythemia vera(3). in a CD45.2 background were isolated. Bone marrow was spun at 8,000 rpm in a PCR tube (with a perforated tip) within an Eppendorf tube for 1 min into 10% fetal calf serum (FCS) media to flush bones. Cells were passed through a 70 uM strainer. Red blood cells (RBCs) were lysed in ammonium chloride-potassium bicarbonate lysis buffer for 10 min on ice. Cells were then mixed 3:2 with CD45.1 C57BL/6 marrow and 2 million cells were tail vein injected into 20 lethally irradiated CD45.1 C57BL/6 recipients ( Figure S4 ).
Flow cytometry
For the in vitro studies, cells were washed in cold phosphate buffered saline (PBS), spun, and then washed in 1X Annexin Binding Buffer. The cells were then spun and resuspended in 1X Annexin Binding Buffer at 5x10 6 /mL. FITC-conjugated Annexin V stain and 7AAD stain were added to 100uL of cell suspension and incubated at room temperature for 15 minutes, protected from light. Data were collected on BD Biosciences LSRFortessa without washing and analysis was performed on FlowJo.
For the in vivo studies, bone marrow and spleen cells were filtered, and red blood cells were lysed and washed in 1X PBS. For chimerism staining, cells were incubated with the following antibodies for 30 minutes on ice in PBS plus 2% bovine serum albumin (BSA): CD11b conjugated to fluorescein isothiocyanate (FITC) (BioLegend), CD45.1 conjugated to eFluor 450 (eBioscience), and CD45.2 conjugated to APC (BioLegend). Data were collected on BD Biosciences LSRFortessa and analysis was performed on FlowJo.
Western Blot
Splenocytes were collected from all experimental and control arms at the time of either their death or the conclusion of the study (25 days), whichever came first, after dosing with the assigned ruxolitinib or control regimen. The mice were sacrificed 2 hours after their final drug treatment, after which cells were extracted, processed and frozen down for Western Blot analysis at a later date. To process the splenocytes, they were passed through a 70 uM filter. Red blood cells were lysed in ammonium chloride-potassium bicarbonate lysis buffer for 10 min on ice. Cells were then spun down and snap frozen on dry ice. Upon thawing at a later date, cells were resuspended in lysis buffer (150 mM NaCl, 20 mM Tris [pH 7.4-7.5], 5 mM ethylenediaminetetraacetic acid, 1% Triton-X, 10% glycerol) containing Protease Arrest (G-Biosciences), Phosphatase Inhibitor Cocktail II (EMD Chemicals). Protein was quantified using the Bio-Rad Bradford protein estimation and 30 to 50 ug was loaded per well in 4% to 12% Bis-Tris electrophoresis gels (Invitrogen). Protein was transferred on to 0.45-micron nitrocellulose membranes. Antibodies used for western blotting included pSTAT3, STAT3, pSTAT5, STAT5 (all from Cell Signaling Technologies) and beta actin.
Cell lines
SET-2 cells (megakaryoblastic cell line established from the peripheral blood of a patient with leukemic transformation of essential thrombocythemia (ET)) were cultured in RPMI-1640 supplemented with 20% FBS.
In vitro assays for determining birth and death rates
SET-2 cells were cultured with varying concentrations of ruxolitinib ranging through 0, 0.1, 0.5, 1 and 2 µM. For each drug concentration, approximately 6 million cells were diluted in 12mL of media in tissue culture flasks and cultured for 48 hours. Three replicate 500uL samples of cell culture were counted at 0, 24 and 48 hours (for each drug concentration) with cell viability analyzer, Vi-cell (Beckman-Coulter), to estimate the total population size at a given time point. Also for each time point and drug concentration, a 1mL sample from each culture was stained with an apoptosis and a viability marker (FITC-Annexin V and 7AAD, respectively; BD Pharmingen) and 50,000 events were analyzed with flow cytometry using a FACScalibur in order to distinguish what portion of the total population consisted of live, dead, and apoptotic cells ( Figure 1A , S1). The data obtained through flow cytometry was analyzed using FlowJo software (Tree Star Inc). Determining these proportions through flow cytometry was crucial to assess the birth and death rates of the cells treated with varying drug concentrations ( Figure 1B, S2 ). However, we must point out that measurements can fluctuate depending on the viability and variability (given different passages) of the cells at the beginning of the experiment since each experimental replicate was not done at the same starting point but rather months apart. Also, the sampling taken from the population at each time point can introduce further variability in the estimated cell counts. Since ultimately a cell line is only an approximation of the in vivo reality, we take into consideration all the variability encountered from the in vitro experiments into our modelling. To fairly assess the trend given by all three replicates taken altogether, we estimate the fit for 100 separate bootstrapping samples re-sampled from all points from all replicates. More details about how the birth and death rates are estimated will be described in detail in the mathematical model section.
Pharmacokinetic analysis
An exponentially decaying surface ( Figure 1E ) was used to model drug plasma concentration over time for multiple doses (pharmacokinetic analysis done by Incyte, data not shown). A negative exponential surface was chosen by combining the simplest canonical pharmacokinetic model of an exponential decay of plasma concentration as a function of dose and the linear relationship between dose and plasma concentration. The surface has the following functional form: , = * * !! * !!"# . The model parameters were estimated using a non-linear least absolute residuals regression.
The mathematical model
To enable re-use of our materials and improve reproducibility and transparency we include the MATLAB code and data used for all the analysis and visualizations contained in this paper in the open repository https://github.com/answermyriddles/rux. The in vitro flow cytometric data allowed us to estimate the population of live, apoptotic and dead cells and these estimates were used to calculate birth and death rates ( Figure S2 ). The change in live cells after a certain time interval, , corresponds to the number of cells that were born ( ) minus the number cells that died ( ) in that interval of time: . Therefore, the rate of change in birth is defined by the rate of change in live cells plus the rate of change in dead cells:
. We denote and .
The death rate was then calculated as . For the purpose of the calculations described above, the population of apoptotic cells was incorporated into the population of dead cells. The cells' birth rates and death rates were fit to experimental data (Figures S1 and S2). The Bayesian Information Criterion was used to choose the best-fitting model ( Figure  S2 ). A linear model was chosen for the birth rate following:
and a logarithmic model was chosen for the death rate following:
To determine the optimal dosing strategy that would minimize the number of cancer cells after treatment, we investigated how varying drug concentrations and treatment schedules differentially affected cell growth. We decided to describe cell proliferation over time as an exponential growth model where the parameters are the cell's birth and death rates (b and d, respectively), which are themselves functions of the drug concentration:
, where and denote the number of cells at time t2 and t1, respectively and ∆ = ! − ! thus t2 >t1. We initialize the population size at the beginning of our simulation with 10 6 cells, approximating the number of cancer cells injected in our murine model. The administration of different concentrations of drug affects the cells' birth and death rates differently; our mathematical model allows us to estimate the cell population size after a given combination of drug dose and treatment length, i.e. a dosing strategy, as in previous studies (4, 5) . We divided the treatment into cycles of seven days and each cycle consisted of a pulse, Ton (an interval of time when the drug was being administered) and a break, Tof f (an interval of time when the drug was not being administered) ( Figure 1C ). We can interpret a schedule where Tof f is zero (there are no breaks) to the equivalent of a chronic dose treatment. We fit our pharmacokinetic data with an exponentially decaying surface ( Figure 1E ), which allowed us to describe the expected plasma concentration of the drug over time. The pharmacokinetic analysis revealed that ruxolitinib plasma concentration decreased significantly, in between dose administrations. The twice daily dosing was done in intervals of 8 and 16 hours, and the pk data suggested that during the latter, cells were exposed to a much lower drug concentration long before the next dose was administered, which could
result in fluctuating cell growth rates in between doses. To account for this possibility, instead of assuming that cells grow at a constant growth rate during both intervals between doses, we updated the cell growth rate, eight hours later, given the expected ruxolitinib plasma concentration at that time point.
The in vitro data used to estimate the birth and death rates showed considerable variability. We hypothesize that there was either technical or biological variability and to study how this variability affected our conclusions we performed a robustness analysis. For the birth rate, we fit each of the replicates individually with a regression model and ran a statistical test (t-test) which revealed that the slopes of replicates 1 and 3 were in fact not significantly different from zero (p-value = 0.06018 and p-value = 0.0600). Replicate 2 suggested a negative slope significantly different from zero (p-value = 0.0378). This suggested different trends for replicates 1 and 3 (unchanged with drug concentration) and replicate 2 (decreasing with drug concentration). We therefore simulated the model considering a birth rate fit to each replicate separately with zero slopes for replicates 1 and 3 (Supplemental figure 7) . Replicates 1 and 3 suggested that an intermittent treatment of 270mg/kg was more efficacious than a chronic treatment while replicate two suggested all intermittent treatments were more efficacious. However, as we were aware of the noise in the in vitro data and made a conservative choice to only test in vivo intermittent treatment doses of 270mg/kg and 360mg/kg.
Although the death rate estimates showed consistent trends across replicates, there were still considerable fluctuations, therefore we included an additional analysis for each birth rate but now for a range of death rate functions (Supplemental figure 8) to illustrate that the simulations for each birth rate were consistent for the whole range of death rate functions. All showed that birth rates fit to replicate 2 would suggest all intermittent dosing strategies to be more beneficial while birth rates fit to replicates 1 and 3 would suggest an intermittent treatment of 270mg/kg, regardless of the choice of death function in the range of our death rate data.
Toxicity constraint
Following the in vitro studies where we determined the birth and death rates of SET-2 cells in the presence of different concentrations of ruxolitinib ( Figure S2 ), our aim was to find the combination of dose and treatment length that would minimize the number of JAK2V617F cells after a four-week treatment period. Thus, we were interested in the dose that resulted in the lowest birth rate and highest death rate of the cancer cells. The death rate of cells is a monotonically increasing function of the drug dose, which would imply that the best dosing strategy would be an infinitely high dose administered indefinitely. However, this is an unrealistic treatment, as it does not take into account the toxicity resulting from high doses of the drug. This is especially true as ruxolitinib is a JAK2 inhibitor and wildtype JAK2 is essential for promoting normal cell growth. In order to determine the optimal dosing schedule, we constrained the model to a range of treatment schedules tolerated in mice. This toxicity constraint was built using previously derived preclinical data (Incyte personal communication), which indicated the maximum number of days a particular dose was tolerated ( Figure S3 ) including that the maximum tolerated chronic dose was 60 mg/kg given daily and that 600 mg/kg could only be safely administered for a maximum of 1 day (longer treatment resulted in death). Unfortunately, the data available was very limited, containing only three data points, which only allowed for a very rough estimate of the toxicity constraint ( Figure S3 ), and could only be fit with a simple linear model. However, as expected, the data supports that the number of days tolerated as a function of dose is monotonically decreasing; that is, the lower the dose, the longer it can be safely administered. Figure S1 . Flow cytometric analysis of SET-2 cells treated with ruxolitinib. SET-2 cells were treated with a range of Ruxolitinib (0, 0.1, 0.5, 1 and 2 uL) for 48 hours. Samples were taken every 24 hours and stained with 7-AAD and FITC-Annexin V for determining live, dead, and apoptotic cell populations. Figure S2 . Birth, death and overall growth rates. Birth and death rates determined based on flow cytometric analysis of SET-2 cells in the presence of Ruxolitinib at different concentrations. The x-axis shows the drug concentrations to which cells were exposed and the y-axis shows (A) the birth and (B) death rates resulting from different concentrations of drug exposure. Mean lines correspond to a model fit to all the data and shaded region shows the 95% confidence interval obtained from 100 bootstrapping samples. (C) Bayesian information criteria was used to compare different possible models and a linear model was chosen for having the lowest BIC. (D) Bayesian information criteria was also used to inform the death rates however, although a linear model had the lowest BIC it resulted in very high death rates and fast death of the cells in the population growth simulation, so we opted for the second best model (logarithmic) which had more biologically plausible predictions. It is important to point out that both the linear and the log model suggested the same two intermittent treatments for testing and therefore choosing one or the other would not have informed the in vivo experiments differently. Figure S3 . Toxicity constraint. Consecutive days mice have been shown to tolerate various doses of Ruxolitinib before the dose becomes toxic (evaluated by death). Figure S4 . In vivo studies of intermittent vs. chronic ruxolitinib dosing. CD45.2-Jak2V617F BM was harvested and mixed with CD45.1-C57BL/6 BM at a 3:2 ratio before injection into lethally irradiated CD45.1-C57BL/6 recipients. After two weeks, these recipients were randomized based on complete blood counts and divided into four experimental groups of 5 mice each. The first group was treated via gavage with vehicle BID for 7 days a week. The second group was treated via gavage with 60 mg/kg ruxolitinib BID for 7 days a week. The third group was treated via gavage with 270 mg/kg ruxolitinib BID for 5 days a week. Finally, the fourth group was treated via gavage with 360 mg/kg for 3 days a week. CBCs were evaluated at the beginning of each week and the trial concluded after 25 days, when the organs were harvested for analysis. Figure S5 . Red blood cell (RBC), white blood cell (WBC) and platelet (PLT) counts measured before treatment, 2-weeks into treatment and at the conclusion of the study for vehicle, chronic 60 mg/kg ruxolitinib and intermittent 270 mg/kg ruxolitinib arms. Data shows some reduction in RBC (significant with p<0.016) and WBC (non-significant with p>0.1) counts in the 270 mg/kg group compared to 60 mg/kg but no noticeable change across groups in PLT counts (see Table 1 for all pairwise Wilcoxon rank sum test comparisons). Table S1 . Wilcoxon rank sum test p-value results on pairwise comparisons between treatment groups show non-significant changes in liver weight between vehicle and both 60mpk and 270mpk treatment groups and indicate no increased liver toxicity in the 270mpk treated cohort. Spleen weight comparisons show a significant difference between the larger spleens from the vehicle group versus the smaller spleens in both 60mpk and 270mpk groups, however no significant difference between spleen sizes in the two treatment groups (60mpk vs 270mpk). Differences between the 270mpk group and two others were significant for hemoglobin and hematocrit, supporting the improved efficacy of the 270mpk treatment at reducing these blood parameters. Differences in white blood cells (WBC) and platelets (PLT) values were non-significant in all pairwise groups comparisons. A. Death rate functions estimated from fitting all data (Fit All) as described in the methods while varying the logarithmic parameter (b in log(bx)) such that the range of functions provide coverage of the data range. B-D Treatment schedules simulated for birth rate functions fit to each replicate for death rate function sens1 (bsens1 = 1.5*bal l). E-G Treatment schedules simulated for birth rate functions fit to each replicate for death rate function sens2 ((bsens1 = 2*bal l)).H-J Treatment schedules simulated for birth rate functions fit to each replicate for death rate function sens3 (bsens1 = 0.7*bal l). K-M Treatment schedules simulated for birth rate functions fit to each replicate for death rate function sens4 (bsens1 = 0.4*bal l). Figure S1 . Figure S2 . Figure S3 . Figure S4 . Figure S5 . Figure S6 . Table S1 . Figure S7 . Figure S8 .
